Showing 5081-5090 of 5693 results for "".
- Analysts Give Gilead’s Remdesivir 50% Chance of Success as COVID-19 Treatmenthttps://modernod.com/news/analysts-give-gileads-remdesivir-50-chance-of-success-as-covid-19-treatment/2477362/Analysts at RBC Capital Markets suggested that it is a toss-up whether Gilead Sciences’ remdesivir will succeed in demonstrating efficacy and ultimately securing approval to treat COVID-19, citing limited dosing results, confounding data and previous disappointments in Ebola. “[The] b
- Vision Expo East Cancelled Due to Coronavirus; Will Consolidate With Vision Expo West in Las Vegashttps://modernod.com/news/vision-expo-east-cancelled-due-to-coronavirus-will-consolidate-with-vision-expo-west-in-las-vegas/2477359/The organizers of Vision Expo announced that they are cancelling the scheduled Vision Expo East meeting scheduled to take place in New York, March 26-29, and consolidate that meeting with Vision Expo West in Las Vegas, Sept. 23-26. The decision was made due to concerns over the spread of the coro
- Jim Mazzo Receives the Ellis Island Medal of Honorhttps://modernod.com/news/jim-mazzo-receives-the-ellis-island-medal-of-honor/2477358/Jim Mazzo, Global President of Ophthalmic Devices with Carl Zeiss Meditec, has been chosen to receive the Ellis Island Medal of Honor in 2020. The Ellis Island Honors Society honors the importance of immigration to America’s prosperity and celebrates the contributions immigrants and their
- Long-Term Visual Acuity Unaffected by Intraocular Lens Implantation After Congenital-Cataract Surgeryhttps://modernod.com/news/long-term-visual-acuity-unaffected-by-intraocular-lens-implantation-after-congenital-cataract-surgery/2477357/Intraocular lens implantation at the time of surgery for congenital cataract during infancy neither improves nor worsens long-term visual acuity, compared with correction with contact lenses, according to findings from the Infant Aphakia Treatment Study (IATS), as
- PRISM Vision Group Announces Agreement With The Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington-2/2477356/PRISM Vision Group announced an agreement to add its newest partner, The Retina Group of Washington (RGW), a provider of retinal and macular care in Washington, D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us and over the past sever
- AAO Alert: Coronavirus Update for Ophthalmologistshttps://modernod.com/news/aao-alert-coronavirus-updates-for-ophthalmologists/2477347/The Academy is sharing important ophthalmology-specific information related to the novel coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was previously known by the provisional name 2019-nCoV. The highly contagious virus can cause a severe respirato
- Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 Genetic Modifier to Treat Retinitis Pigmentosahttps://modernod.com/news/nature-gene-therapy-publishes-preclinical-data-of-ocugens-ocu400-genetic-modifier-to-treat-retinitis-pigmentosa/2477345/Ocugen announced the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases. OCU400 (NR2E3-AAV) has received two orphan drug designatio
- Prism Vision Group Announces Agreement With the Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington/2477344/Integrated eyecare services organization PRISM Vision Group announced an agreement to add The Retina Group of Washington (RGW), which provides retinal and macular care in Washington D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us an
- Registration Open for Eyecelerator, a New Conference Aimed at Accelerating Eye Care Advancementshttps://modernod.com/news/registration-open-for-eyecelerator-a-new-conference-accelerating-eye-care-advancements/2477339/Registration is now open for Eyecelerator, a new business conference aimed at furthering ophthalmic innovation. The conference is a joint venture between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS). The inaugural Eyecelerator con
- EyePoint Pharmaceuticals Announces Positive Topline 36-Month Follow-up Data for Second Phase 3 Study of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-36-month-follow-up-data-for-second-phase-3-study-of-yutiq/2477336/EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second phase 3 trial of Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. “The d